CERA

Science and Research

PANDA-1: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration

The purpose of this 24-month clinical study is to evaluate the efficacy and safety dose levels of conbercept intravitreal injection, as compared to the aflibercept (Eylea) intravitreal injection, in subjects with neovascular age-related macular degeneration.

Overview

This is a multicentre, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomised trial, which will randomise approximately 1140 subjects in a ratio of 1:1:1 to receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept.

The trial includes a screening period of less than or equal to 14 days, followed by a treatment period of 92 weeks (last assessment at 96 weeks) with primary efficacy analysis at 36 weeks.

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.